NRXBF (NurExone Biologic) COGS-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic COGS-to-Revenue?

NurExone Biologic's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.00 Mil. Its Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

NurExone Biologic's COGS to Revenue for the three months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NurExone Biologic's Gross Margin % for the three months ended in Dec. 2024 was N/A%.

NurExone Biologic COGS-to-Revenue Historical Data

The historical data trend for NurExone Biologic's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic COGS-to-Revenue Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial										-	-	-	-	-

NurExone Biologic COGS-to-Revenue Calculation

NurExone Biologic's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NurExone Biologic's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

NurExone Biologic (OTCPK:NRXBF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NurExone Biologic's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NurExone Biologic COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.